All India Institute of Medical Sciences (AIIMS) Delhi Conducts India's First Dedicated Clinical Trial of Advanced Brain Stent

Key facts

• All India Institute of Medical Sciences (AIIMS) Delhi has achieved a milestone in stroke care by conducting the country's first dedicated clinical trial of a cutting-edge and advanced brain stent made for treating severe strokes.
• The GRASSROOT trial, which evaluated the Supernova stent (Gravity Medical Technology), has found excellent safety and efficacy outcomes in the treatment of severe strokes, say officials.
• The results were published in the ‘Journal of Neurointerventional Surgery’ (JNIS), part of the prestigious British Medical Journal group.
• AIIMS Delhi was the national coordinating centre and the lead enrolling site for the GRASSROOT trial – India's first clinical trial of a new and advanced stroke treatment device, the Supernova stent.
• Earlier this year, data from the GRASSROOT trial were accepted by the Central Drugs Standard Control Organisation (CDSCO) and the Supernova stent-retriever was approved for routine use in India.
• This is the nation's first stroke device cleared based on a domestic clinical trial.
• Conducted across eight centres, the trial marks a milestone for the Make-in-India initiative and positions India as a global player in advanced stroke care.
• Developed by Gravity Medical Technology, Supernova is designed for India’s diverse patient population, where strokes often strike patients at a younger age than in the West.
• The device has already treated more than 300 patients in Southeast Asia.
• It will now be manufactured and made available in India at affordable prices, offering new hope to the 1.7 million Indians who suffer strokes each year.